Status:

UNKNOWN

68Ga-TCR-FAPI PET/CT in Patients With Various Types of Cancer

Lead Sponsor:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Collaborating Sponsors:

Peking University

Peking University Cancer Hospital & Institute

Conditions:

Malignant Tumor

Positron Emission Tomography

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Adding targeted covalent radiopharmaceutical (TCR) moiety to fibroblast activation protein inhibitor (FAPI) can increase tumor uptake and tumor retention in pre-clinical studies. This study is an open...

Detailed Description

TCR-FAPI can covalently bind to FAP that increase tumor uptake and tumor retention in pre-clinical studies, which elevates the ability for cancer imaging and facilitates the targeted radionuclide ther...

Eligibility Criteria

Inclusion

  • Suspected to have malignant tumors (supported by MRI and/or CT and/or tumor markers and/or pathology report), the tumor may be newly diagnosed or previously treated;
  • Meet the indications for PET examination, show a clear indication and no contraindications;
  • Have a performance status of score ≥ 80 on KPS scale or score 0-1 points on ECOG scale, a relatively good general situation;
  • No major organ dysfunction (heart, lung, liver, kidney and other major organ include), acute or life-threatening status of infection;
  • Be ≥ 18 years of age;
  • Be willing and able to understand the research content and provide written informed consent/assent for the trial.

Exclusion

  • Have a history of imaging agent allergies;
  • Does not meet the PET-CT scan sedation requirements, or has contraindications for PET-CT examination;
  • Be pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial.

Key Trial Info

Start Date :

May 5 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 30 2025

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT06084767

Start Date

May 5 2023

End Date

December 30 2025

Last Update

October 23 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Peking University Cancer Hospital

Beijing, China